MYRIAD GENETICS INC
No SEC Form 4 filings for $MYGN in the last 30 days.
See all $MYGN insider activity →Myriad Genetics (MYGN) shares fell 7.1% premarket after Piper Sandler downgraded the stock to Underweight, cutting its price target to $2.00 from $5.45. The firm cited concerns over the company's profitability and weak Q2 2026 results, including a 10.5% year-over-year revenue decline. The broader market also declined, with the NASDAQ down 0.9%.
BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
Roblox (RBLX), Hertz (HTZ) and Myriad Genetics (MYGN) fell to 52-week lows as investors cited weaker outlooks and operational issues. RBLX dropped after Q2 revenue of $1.47B missed expectations and it withdrew its 2026 outlook. HTZ slid on margin pressure and $11.6B debt. MYGN sank after Q2 revenue of $190.7M missed and it cut its full-year forecast.
Over the past 7 days, alphai's AI scored 2 news stories mentioning MYGN (MYRIAD GENETICS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MYGN coverage spans earnings, market movers and technology.
Analyst downgrade with a sharp price‑target cut triggered a notable intraday sell‑off.
Weak earnings and guidance miss likely pressure the stock.
Guidance reset and profitability target suspension materially worsened the outlook, supporting further de-risking.
Guidance cut tied to prenatal test weakness implies near-term demand softness and margin pressure risk.
The article frames a revenue reset driven by pricing and payer reimbursement pressure, with guidance suspension increasing downside uncertainty.
alphai scores every news story that mentions MYGN with an AI model for sentiment and relevance, and aggregates insider trades from MYRIAD GENETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Myriad Genetics (MYGN) shares fell 7.1% premarket after Piper Sandler downgraded the stock to Underweight, cutting its price target to $2.00 from $5.45. The firm cited concerns over the company's profitability and weak Q2 2026 results, including a 10.5% year-over-year revenue decline. The broader market also declined, with the NASDAQ down 0.9%.
2 min readBioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
3 min readRoblox (RBLX), Hertz (HTZ) and Myriad Genetics (MYGN) fell to 52-week lows as investors cited weaker outlooks and operational issues. RBLX dropped after Q2 revenue of $1.47B missed expectations and it withdrew its 2026 outlook. HTZ slid on margin pressure and $11.6B debt. MYGN sank after Q2 revenue of $190.7M missed and it cut its full-year forecast.
4 min readSimply Wall St reports Myriad Genetics (MYGN) shares are down 49% after the company cut its 2026 revenue outlook, citing weakness in prenatal testing. The piece references analyst fair value estimates and highlights potential positive and negative factors for investors, but provides no specific new financial figures beyond the outlook cut.
2 min readSimply Wall St reports Myriad Genetics (MYGN) shares fell nearly 47% in a day after results showed a revenue reset and loss fears. Q2 revenue was $190.7m, down 11% year over year, and full-year 2026 sales guidance was cut to $770m to $790m. Adjusted EBITDA guidance was suspended.
6 min readMyriad Genetics (MYGN) suspended adjusted EBITDA guidance due to uncertainty around initiatives. In Q2 it reported an adjusted EBITDA loss of $16.9M and adjusted loss per share of $0.25. Gross margin fell to 66.6% (66.6% excluding an $11M estimate impact: 68.4%). Liquidity was about $190M. Management cited worsening payer reimbursement friction and launched revenue-cycle and efficiency initiatives.
6 min readMyriad Genetics said it rebuilt its AI document-processing tool, Image Genius, after earlier versions were costly and slow. Working with AWS, it moved the platform to Amazon Bedrock. Myriad reported processing time fell from about 10 minutes to 20 seconds per document and saved about 300 staff hours monthly on ~9,000 prior authorizations. Rollout is planned into 2027.
6 min readAnalyst estimates compiled by FactSet show Myriad Genetics’ average 12-month price target cut to $5.75 from $6.14. The range is $4 to $10 per share, implying about 7% upside versus the Jul. 30 close. Consensus remains “Hold” with 2 Buys, 5 Holds, and 2 Sells.
1 min readGenetic testing company Myriad Genetics (NASDAQ: MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out by accessing our full research report, it’s free.
4 min readMYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability Highl ights • Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% de
6 min read
